T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of arenaviruses to treat solid tumors -- Düsseldorf, Germany, October 14 ...
Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...
Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...
The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical ...
The U.S. Food and Drug Administration (FDA) has updated the safety labeling for Carvykti, the multiple myeloma therapy ...
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025/CNW/ — Eight new oncology approvals between July and September 2025 marked a pivotal quarter ...
ORR and 79% DCR observed in heavily pretreated TMB-H or MSI-H/dMMR tumors across six major solid tumor types, including colorectal, lung, breast, ...
Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback